A HAZARDOUS WASTE - ISRAEL CHEMICALLIMITED’S SAP IMPLEMENTATION

July 2, 2019

Israel Chemical Limited (ICL) is an Israel-based chemical company with global operations. The company grew by leaps and bounds through acquisitions and embarked on an ambitious program to deploy a common SAP-based operating template across its three operating units. The initial program definition indicated a project cost of approximately $120M USD, but ultimately the expected costs of the program ballooned to $500M and the program was stopped before any major implementation began.  What followed was a write-off of $290M in project costs, the resignation of the CEO, and a freshly minted lawsuit against IBM filed in an Israeli district court.

Spotlight

ERYTECH Pharma

Founded in 2004, Erytech is a biopharmaceutical company developing innovative therapies to target unmet medical needs, particularly in the fields of cancer and orphan diseases. Erytech’s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. Encapsulation offers a number of benefits as compared to free-form compounds, reducing the potential for allergic reactions and allowing the therapeutic substance to remain longer in the body. Its first product, working by starving tumors, has completed its phase III development and will provide a therapeutic solution to patients with relapsed and refractory acute lymphoblastic leukemia.

OTHER WHITEPAPERS
news image

Chemicals supply chain: how to catch up the race!

whitePaper | December 13, 2019

The chemical industry has enjoyed strong and consistent performance over the last decade. The market is now being affected by new challenges, from increased global competition and changing customer requirements to disruptive new technologies while increased demand for sustainability, safety, and efficiency is changing not only the way companies work, but the products they produce.

Read More
news image

THE INTELLIGENT ENTERPRISE FOR THE CHEMICAL INDUSTRY

whitePaper | April 7, 2022

Mastering future challenges and delivering new customer experiences through innovative products, services, and business models

Read More
news image

Three Keys to Recession Proofing the Chemical Industry Supply Chain

whitePaper | January 27, 2023

Most chemical companies are reporting strong revenue growth, fueled by significant pricing increases; but they also cite rising raw materials, energy, and logistics costs as current concerns, combined with softening demand in most segments.

Read More
news image

Rethinking the Refining and Petrochemicals Industry

whitePaper | September 15, 2022

Crude oil has been used to produce transportation fuel for many decades. But market factors may make it necessary for organizations to consider oil-to-chemical complexes to maintain a competitive edge in today’s global market.

Read More
news image

Flow Measurement for Emissions Monitoring

whitePaper | February 25, 2023

Monitoring emissions has been a major concern at industrial sites, including those in the chemical process industries (CPI), for the past few decades, but a number of factors are currently aligned that elevate the importance of proper monitoring, and amplify the consequences of failing to do so reliably and accurately.

Read More
news image

A META-ANALYSIS OF ROAD TRANSPORT EMISSIONS MODELS

whitePaper | May 22, 2022

The authors thank Pramoda Gode, Joshua Miller of ICCT, Puneet Kamboj of CEEW, Gerald Ollivier of the World Bank, and Pierpaolo Cazzola and Craglia Matteo, both of ITF, for helpful reviews. Any errors are the authors’ own.

Read More

Spotlight

ERYTECH Pharma

Founded in 2004, Erytech is a biopharmaceutical company developing innovative therapies to target unmet medical needs, particularly in the fields of cancer and orphan diseases. Erytech’s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. Encapsulation offers a number of benefits as compared to free-form compounds, reducing the potential for allergic reactions and allowing the therapeutic substance to remain longer in the body. Its first product, working by starving tumors, has completed its phase III development and will provide a therapeutic solution to patients with relapsed and refractory acute lymphoblastic leukemia.

Events